Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
AnaptysBio (NASDAQ: ANAB), a clinical-stage biotechnology company specializing in innovative immunology therapeutics, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. Daniel Faga, the company's president and chief executive officer, will deliver a presentation on Wednesday, February 5, 2025, at 1:00 PM ET / 10:00 AM PT.
Interested parties can access a live webcast of the presentation through the investor section of the Anaptys website at http://ir.anaptysbio.com/events. The presentation recording will remain available for replay for a minimum of 30 days after the event.
AnaptysBio (NASDAQ: ANAB), un'azienda biofarmaceutica in fase clinica specializzata in terapie immunologiche innovative, ha annunciato la sua partecipazione alla prossima Guggenheim SMID Cap Biotech Conference. Daniel Faga, presidente e amministratore delegato dell'azienda, farà una presentazione mercoledì 5 febbraio 2025, alle 13:00 ET / 10:00 PT.
Le parti interessate possono accedere a una diretta della presentazione tramite la sezione investitori del sito web di Anaptys all'indirizzo http://ir.anaptysbio.com/events. La registrazione della presentazione rimarrà disponibile per la visione per un minimo di 30 giorni dopo l'evento.
AnaptysBio (NASDAQ: ANAB), una empresa biofarmacéutica en etapa clínica que se especializa en terapias inmunológicas innovadoras, ha anunciado su participación en la próxima Guggenheim SMID Cap Biotech Conference. Daniel Faga, presidente y director ejecutivo de la compañía, presentará una conferencia el miércoles 5 de febrero de 2025, a la 1:00 PM ET / 10:00 AM PT.
Los interesados pueden acceder a una transmisión en vivo de la presentación a través de la sección de inversores de la página web de Anaptys en http://ir.anaptysbio.com/events. La grabación de la presentación estará disponible para su reproducción durante un mínimo de 30 días después del evento.
AnaptysBio (NASDAQ: ANAB), 혁신적인 면역학 치료제에 전문화된 임상 단계 생명공학 회사가 다가오는 구겐하임 SMID 캡 생명공학 컨퍼런스에 참여한다고 발표했습니다. 다니엘 파가 CEO가 2025년 2월 5일 수요일, 오후 1시 ET / 오전 10시 PT에 발표를 진행할 예정입니다.
관심 있는 분들은 Anaptys 웹사이트의 투자자 섹션을 통해 발표의 실시간 웹캐스트를 시청할 수 있습니다. 발표 녹화는 이벤트 후 최소 30일 동안 재생할 수 있습니다.
AnaptysBio (NASDAQ: ANAB), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapeutiques immunologiques innovantes, a annoncé sa participation à la prochaine Conférence Guggenheim SMID Cap Biotech. Daniel Faga, le président et directeur général de l'entreprise, présentera le mercredi 5 février 2025, à 13h00 ET / 10h00 PT.
Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section investisseurs du site Web d'Anaptys à l'adresse http://ir.anaptysbio.com/events. L'enregistrement de la présentation restera disponible en rediffusion pendant un minimum de 30 jours après l'événement.
AnaptysBio (NASDAQ: ANAB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf innovative immunologische Therapien spezialisiert hat, hat seine Teilnahme an der kommenden Guggenheim SMID Cap Biotech Conference angekündigt. Daniel Faga, der Präsident und CEO des Unternehmens, wird am Mittwoch, den 5. Februar 2025, um 13:00 Uhr ET / 10:00 Uhr PT eine Präsentation halten.
Interessierte können über den Investorenbereich der Anaptys-Website unter http://ir.anaptysbio.com/events auf ein Live-Streaming der Präsentation zugreifen. Die Aufzeichnung der Präsentation bleibt mindestens 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT.
A live webcast of the presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. A replay of the webcast will be available for at least 30 days following the event.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, soon to enter clinical development. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
When is AnaptysBio (ANAB) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch AnaptysBio's (ANAB) Guggenheim Conference presentation?
How long will the replay of ANAB's Guggenheim Conference presentation be available?
Who is presenting for AnaptysBio (ANAB) at the Guggenheim SMID Cap Biotech Conference?
